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1. INTRODUCTION 
The present “Report on the Development, Validation and Legal Acceptance of Alternative 
Methods to Animal Tests in the Field of Cosmetics” is the eighth report concerning this issue 
presented by the Commission. It reflects the state of play in terms of the number and type of 
experiments on animals relating to cosmetic products in 2007 and 2008, the current status of 
alternative replacement methods, and the acceptance and recognition of alternative methods at 
international level. The report is produced in order to comply with Article 9 of Council 
Directive 76/768/EEC1 of 27 July 1976 on the approximation of the laws of the Member 
States relating to cosmetic products (hereinafter “Cosmetics Directive”), as amended by the 
European Parliament and Council Directive 2003/15/EC of 27 February 2003. It is the fourth 
report on the basis of the 7th Amendment to the Cosmetics Directive. 
This present report is the last report covering the period before the coming into force of the 
full testing ban for ingredients and combinations of ingredients for cosmetics and the 
marketing ban for all human health effects with the exception of repeated-dose toxicity, 
reproductive toxicity and toxicokinetics on 11 March 2009.  
2. NUMBER AND TYPE OF EXPERIMENTS RELATING TO COSMETIC PRODUCTS 
CARRIED OUT ON ANIMALS 
2.1. Legal Background 
According to Article 9(a) of the Cosmetics Directive, every year the Commission shall 
present a report to the European Parliament and the Council on progress made in the 
development, validation and legal acceptance of alternative methods. The report shall contain 
precise data on the number and type of experiments relating to cosmetic products carried out 
on animals. The Member States shall be obliged to collect that information in addition to 
collecting statistics as laid down by Council Directive 86/609/EEC of 24 November 1986 on 
the approximation of laws, regulations and administrative provisions of the Member States 
regarding the protection of animals used for experimental and other scientific purposes 
(Experimental Animals Directive). The Experimental Animals Directive includes 
requirements to report at regular intervals, not exceeding three years, on the number and kinds 
of animals used in experiments. 
The ban on the testing of finished cosmetic products has been in force since 11 September 
2004, whereas the ban on testing ingredients or combinations of ingredients, applies since 11 
                                                 
1 Council Directive of 27 July 1976 on the approximation of the laws of the Member States relating to 
cosmetic products (76/768/EEC); OJ L 262, 27.9.1976, p. 169 
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March 2009, irrespective of the availability of alternative non-animal tests. The marketing ban 
applies since 11 March 2009, for all human health effects with the exception of repeated-dose 
toxicity, reproductive toxicity and toxicokinetics. For the latter endpoints the marketing ban 
will apply as of 11 March 2013, regardless of the availability of alternative non-animal tests. 
The Commission must study the progress and compliance with the deadlines, as well as 
possible technical difficulties in complying with the ban. By 2011 the Commission must, in 
particular, study whether for technical reasons one or more tests covered by the 2013 deadline 
will not be developed and validated before March 2013. It shall inform the European 
Parliament and the Council and will, if appropriate, put forward a legislative proposal. 
These provisions have not been changed within the new Cosmetics Regulation2. 
2.2. Animal Testing Data3 
For the present report, 27 Member States supplied information on animal tests carried out for 
the safety of cosmetic products in 2007 and 2008. According to the information submitted, 
cosmetic ingredients have only been tested on animals in the territories of France and Spain. 
These Member States provided detailed information, including the testing period, the 
toxicological endpoint, species of animals used for experiments and number of animals used 
for testing (Table 2).  
In total, 1818 animals in 2007 and 1510 animals in 2008 were used in tests carried out in 
relation to the safety of cosmetic ingredients (Table 1). The other 25 Member States reported 
that no such animal tests where performed in their territory in 2007/2008 or that they cannot 
provide the information for the reasons explained below (see 2.3.1). 
Number of animals used in Member States (2007/2008) – Table 1 
 NUMBER OF ANIMALS USED ANIMALS USED 
 2007 2008  
SPAIN 12 No data Rabbits 
FRANCE 
1806  1510 
 
Mice, rats, guinea 
pigs, rabbits 
Total 1818 1510  
 
                                                 
2 Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 
on cosmetic products; OJ L 342, 22.12.2009, p. 59 
3 See reservations on the accuracy of data under 2.3 “Evaluation of submitted data”  
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Number of Animals Used in Relation to Toxicological Endpoints (2007/2008) – Table 2 
TYPES OF TESTS / COUNTRIES SPAIN FRANCE 
 2007 2008 20074 2008 
Skin irritation 12 No 
data 
126 82 
Eye irritation   61 25 
Skin sensitisation   1154 1283 
Mutagenicity   159 54 
Non-lethal toxicity   266 66 
The total number of animals used for testing the safety of cosmetics showed a slight increase 
compared to the last report's figures for 2006 (2005: 2 276, 2006: 1 329).  
Nevertheless, the reported number of animals used for the testing of cosmetics or toiletries 
remains small compared to the total number of animals used for experimental and other 
scientific purposes. The Fifth Report on the Statistics on the Number of Animals used for 
Experimental and other Scientific Purposes in the Member States of the European Union5 
mentioned that 8% of the total number of animals used for experimental purposes are used for 
toxicological and other safety evaluations, of which cosmetics represent 0.5%. 
2.3. Evaluation of submitted data 
In August 2008, the Commission asked Member States to send accurate data on the number 
and type of experiments relating to cosmetic ingredients carried out on animals in 2007 and 
2008, in accordance with Article 9(a) of the Cosmetics Directive. The Commission specified 
that this information should also explain precisely what the figures represent and the way in 
which they were collated. As for the last report, the Commission annexed to this request the 
guidelines drawn up in order to facilitate accurate generation and collation of animal testing 
data relating to cosmetic products. 
The Commission also requested, in view of the deadline of 11 March 2009, information 
regarding the way Member States intend to ensure the implementation of the marketing ban as 
provided by Article 4a of the Cosmetics Directive.  
2.3.1. Main explanations given by Member States: 
The majority of Member States replied that no animal testing in relation to cosmetic products 
was performed in 2007 and 2008 in their territory. The main explanations they gave to 
substantiate their replies were the following: 
– National legislation prohibits the carrying out of animal experiments in order to test 
and develop cosmetic products and their ingredients.  
                                                 
4 Total figures includes 40 animals used for other tests not specified 
5 5.11.2007, COM(2007) 675 final 
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– National legislation stipulates that animal testing must be authorised in order to be 
lawfully performed, and therefore:  
• no authorisation was given to laboratories to test and develop cosmetic products 
and their ingredients; 
• there are no approved establishments for animal experiments relating to cosmetic 
products. 
– The following do not exist on national territory: 
• testing facilities for animal testing related to human health; or 
• laboratories complying with the requirements of good laboratory practice where 
non-clinical studies of the health and environmental safety of substances could be 
carried out. 
– The authorities responsible for checking cosmetic products and carrying out market 
surveillance do not conduct or commission animal experiments for the purposes of 
such checks. 
– A letter and a questionnaire were sent to representatives of cosmetic product 
manufacturers and the answer indicated that no tests were carried out. 
– Competent authorities checked the product information file which, according to 
Article 7a, paragraph 1(h) of the Cosmetics Directive, must also contain data on 
animal testing. They found nothing to suggest that chemical substances used as 
ingredients in cosmetics had been tested on animals. 
2.3.2. Details of difficulties encountered by Member States 
Some Member States elaborated on their replies by mentioning the difficulties they had in 
collecting the information. 
As pointed out in the previous reports, chemicals are rarely tested on animals solely for their 
use as ingredients in cosmetics, and the majority of animal tests are conducted for multiple 
uses by manufacturers of chemical substances (industry assumes that approximately 80-90% 
of cosmetic ingredients are tested for multiple uses). Therefore, some Member States 
acknowledged that it is difficult to determine which testing has been carried out with a view 
to cosmetic purposes. 
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2.3.3. Initiatives taken by Member States for the collection of data 
In view of the efforts requested of the Member States by the Commission to deliver the 
appropriate information, some Member States described the measures taken to improve data, 
such as: 
– A notice was sent to all license holders authorised to carry out animal experiments 
specifying that they must, when submitting information on experiments in 
connection with cosmetics, supply information on the number and type of 
experiments conducted, including the purpose of the experiments and the type of 
cosmetic product or toiletry the substances tested were expected to be included in 
(skin cream, toothpaste etc.). 
The notice also stated that those who had conducted experiments on animals in tests 
on multipurpose substances under chemicals legislation must supply information on 
the extent to which one of the secondary purposes of the substances could be used in 
cosmetics or toiletries. 
– A survey based on a questionnaire involving the key laboratories most likely 
involved in animal testing was carried out. 
– On-the-spot inspections at bodies carrying out toxicological tests on behalf of third 
parties were carried out and more information was requested by directly contacting 
laboratory managers.  
2.3.4. Measures foreseen in the light of upcoming marketing ban  
In view of the upcoming marketing ban Member States have essentially informed the 
Commission that they will use the market surveillance instruments in place in order to enforce 
the marketing ban. The main tool mentioned is the control of the information provided in the 
product information file in accordance with Article 7a of the Cosmetics Directive, and in 
particular under Article 7a (1) (h). It was also mentioned that the provisions of the new 
Cosmetics Regulation6 could facilitate this tasks as it spells out, in more detail, the content of 
the product information file. Some Member States gave more detailed information about the 
responsible market surveillance authorities, as well as plans on project-based checks. A 
number of Member States also planned to particularly draw the attention of market 
surveillance authorities to the ban through guidance notes and similar tools.  
2.3.5. Conclusion 
The Commission acknowledges that Member States have made efforts to improve the 
availability of data and that the overall availability has improved. However, the Commission 
continues to be concerned about the accuracy of the figures being reported, and this concern is 
shared by Member States.  
The main issue relates to multiple use substances. Some Member States, when mentioning 
that no animal testing has been performed for cosmetic ingredients, reported that no 
toxicological tests were carried out for multiple or uncertain purposes where it could be 
                                                 
6 Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 
on cosmetic products; OJ L 342, 22.12.2009, p. 59 
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considered that the substance might be used as an ingredient in cosmetic products. Legislation 
stipulating that animal testing must be authorised in order to be lawfully performed appears a 
useful tool to determine the purpose of testing. 
The Commission considers that the information held according to Article 7a (1) (h) is also a 
valuable source of information.  
3. PROGRESS IN THE DEVELOPMENT, VALIDATION AND LEGAL ACCEPTANCE OF 
ALTERNATIVE METHODS 
3.1. Legally Accepted Replacement Methods 
3.1.1. Under Annex IX of the Cosmetics Directive 
Annex IX of the Cosmetics Directive “lists the alternative methods validated by the European 
Centre on Validation of Alternative Methods (ECVAM) of the Joint Research Centre 
available to meet the requirements of this Directive and which are not listed in Annex V to 
Council Directive 67/548/EEC on the approximation of laws, regulations and administrative 
provisions relating to the classification, packaging and labelling of dangerous substances”. 
The purpose of Annex IX of the Cosmetics Directive is to supplement Annex V of Council 
Directive 67/548/EEC. Annex IX was created in order to ensure, without delay, the regulatory 
acceptance of alternative methods that would not be applicable to the whole chemical sector, 
but only to the cosmetic sector. Considering that ECVAM did not validate alternative 
methods to animal testing that would not be applicable to the whole chemical sector, Annex 
IX was not amended in 2008 and 2009 and is still empty. 
3.1.2. Council Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods 
pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the 
Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals 
(REACH)  
Directive 2006/121/EC7 of the European Parliament and of the Council provided for the 
deletion of Annex V of Council Directive 67/548/EEC as from 1 June 2008. The Commission 
has adopted an implementation Regulation under Regulation 1907/2006 on REACH, which 
brings together, in one Regulation all the test methods contained previously in Annex V to 
Directive 67/548/EEC. This is Regulation 440/2008/EC8, which now also includes: 
– B.10. Mutagenicity: In vitro mammalian chromosome aberration  
– B.13/14. Mutagenicity: Reverse mutation test using bacteria  
– B.17. Mutagenicity: In vitro mammalian cell gene mutation test 
                                                 
7 Directive 2006/121/EC of the European Parliament and of the Council of 18 December 2006 amending 
Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions 
relating to the classification, packaging and labelling of dangerous substances in order to adapt it to 
Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction 
of Chemicals (REACH) and establishing a European Chemicals Agency, OJ L 396 of 30.12.2006. 
8 Council Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to 
Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, 
Evaluation, Authorisation and Restriction of Chemicals (REACH) , OJ L 142 of 31.05.2008 
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– B. 40. In vitro skin corrosion: transcutaneous electrical resistance test (TER), equivalent to 
the OECD TG 430 (2004); 
– B. 40 Bis. In vitro skin corrosion: human skin model test, equivalent to the OECD TG 431 
(2004); 
– B. 41. In vitro 3T3 NRU phototoxicity test, equivalent to OECD TG 432 (2004); 
– B.42. Skin sensitisation: Local lymph node assay, equivalent to the OECD TG 429 (2002) 
(Note: this is not a replacement test); 
– B. 45. skin absorption (skin penetration): in vitro Method, equivalent to the OECD TG 428 
(2004); 
– B.469. In vitro skin irritation. Reconstructed human epidermis model test  
3.2. Progress in Development and Validation of Alternative Approaches 
3.2.1. ECVAM Technical Report 
ECVAM prepared a “ECVAM Technical Report” covering the period 2008-200910. It 
assesses the possibility of fully replacing animal tests before the cut-off dates set out in 
Article 4a of the Cosmetics Directive and provides detailed information, including an 
overview table, on the ECVAM activities and progress in relation to the respective endpoints. 
3.2.1.1. For the end points falling under the 2009 deadline 
Endpoints falling under the 2009 deadline of the marketing ban are skin corrosivity, skin 
irritation, dermal absorption, mutagenicity/genotoxicity, phototoxicity, acute toxicity and eye 
irritation. Alternative methods are currently available for all of these (see 3.1.2), with the 
exception of the last two, eye irritation and acute toxicity. However in relation to 
mutagenicity/genotoxicity, these tests are prone to an unacceptable rate of false positive 
results. ECVAM is working on improving the in vitro testing battery to address this. 
For eye irritation and acute toxicity several assays were validated by ECVAM, however none 
of them can fully replace animal testing in risk assessment. Testing strategies which combine 
the validated assays are currently under development and evaluation, with the aim to 
completely replace the animal test for eye irritation. Further results are expected by 2011. 
3.2.1.2. For the endpoints falling under the 2013 deadline 
Endpoints falling under the 2013 deadline of the marketing ban are repeated-dose toxicity 
(including skin sensitisation and carcinogenicity), toxicokinetics and reproductive toxicology. 
For these no replacement alternatives are available yet and the situation is much more critical. 
                                                 
9 Included by COMMISSION REGULATION (EC) No 761/2009 of 23 July 2009 amending, for the 
purpose of its adaptation to technical progress, Regulation (EC) No 440/2008 laying down test methods 
pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the 
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) 
10 The technical report is available on the ECVAM website http://ecvam.jrc.ec.europa.eu/ 
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Toxicokinetics and metabolism in vitro and in silico test systems are of crucial importance to 
discard artifactual findings secondary to the in vitro environment. A collaborative effort 
between industry, academia, the European Commission and the three validation bodies 
(ECVAM11, ICCVAM12 and JACVAM13) was therefore set up to validate an in vitro 
metabolic competent test system as an important building block in integrated testing strategies 
for the complex endpoints. 
For the endpoint on carcinogenicity, three variants of the cell transformation assay in vitro 
were validated according to modules 1 to 4 of the ECVAM modular approach and will shortly 
be submitted for ESAC peer review. In the field of skin sensitisation, three promising in vitro 
methods [the Direct Peptide Reactivity Assay (DPRA), the human Cell Line Activation Test 
(h-CLAT) and the Myeloid U939 Skin Sensitisation Test (MUSST)] were sufficiently 
optimised by industry and were accepted in 2009 by ECVAM for entering prevalidation.  
In the area of reproductive toxicology, some promising methods, which were developed under 
Reprotect, an EU-funded collaborative research project in which ECVAM was also involved, 
may be submitted to ECVAM for (pre)validation and some in vitro methods for the 
identification of endocrine disruptors are currently under validation. A reduction in the 
number of animals used for reproductive toxicity testing is envisaged with the ongoing work 
that advocates a modular approach to the extended one-generation reproduction study (Moore 
et al., 2009).  
For the endpoints falling under the 2013 deadline, the lack relevant methods to fully replace 
the animal tests remains a challenge. 
3.2.2. Scientific Committee on Consumer Safety (SCCS) statements 
In December 2009 the SCCS issued a Memorandum on "Alternative Test Methods in Human 
Health Safety Assessment of Cosmetic Ingredients in the European Union"14, in which it 
gives advise on the overall status of available alternative methods and their potential use in 
the human health risk assessment process of cosmetic ingredients and finished products. 
In January 2009 the SCCP (Scientific Committee on Consumer products, now SCCS) issued a 
position statement on genotoxicity/mutagenicity testing of cosmetic ingredients without 
animal experiments15. In this statement the SCCP in particular underlines the high number of 
false positives (see 3.2.1.1.).  
 
The concerns expressed in December 2007 by the SCCP16 in relation to the in vitro test 
EPISKIN™ for skin irritation testing have been taken up and the test has been included in 
Part B of Commission Regulation No 440/2008 as test method B.46. The SCCS however still 
has concerns relating to the use of this method for coloured substances.  
 
 
                                                 
11 European Centre for the Validation of Alternative Methods 
12 Interagency Coordinating Committee on the Validation of Alternative Methods, United States  
13 Japanese Centre for the Validation of Alternative Methods 
14 SCCS/1294/10 
http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_s_001.pdf 
15 SCCP/1212/09 http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_s_08.pdf 
16 SCCP/1145/07 http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_s_07.pdf 
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3.2.3. Support of research activities by the Commission  
Developing effective and novel alternative methods has been a priority under the Framework 
Research Programmes of the European Union for more than 20 years. The results of the 
ongoing research in relation to alternative testing strategies have recently been published17. To 
address the lack of methods replacing animal tests in the assessment of toxic effects of 
chronic exposure, the Commission has launched a call with a budget of €25 million entitled 
“Towards the replacement of repeated dose systemic toxicity testing in human safety 
assessment”18. The cosmetics industry has committed to match the funding given by the 
European Commission, making a total of €50 million available for this research. 
The Ethics Review of all research project proposals involving animal experimentation has 
contributed to the enforcement of EU animal welfare and experimentation standards and has 
strengthened the applicability of the "3 Rs" (replacement, reduction and refinement) principles 
when testing proposals are reviewed in the context of the evaluation procedure for the 
purposes of the 7th Research Framework Programme. 
3.2.4. Colipa (The European Cosmetic Toiletry and Perfumery Association) 
Colipa, with its research programme on Alternative Approaches to Animal Testing, plays an 
important role in supporting the development, validation and acceptance of alternative 
approaches in order to replace animal use. For eye irritation, Colipa submitted to ECVAM at 
the beginning of 2008 results from the optimization of the two most advanced Human 
Reconstructucted Tissue models19. For genotoxicity and mutagenicity, Colipa is working to 
develop approaches to reduce the “false positive” rate of in vitro mammalian cell genotoxicity 
assays and to develop genotoxic assays in 3D human skin models. For skin allergy, Colipa 
aims to strengthen the understanding of how chemicals react with the skin and immune 
system cells to cause skin allergies. Colipa has proposed three methods to ECVAM, which are 
currently under prevalidation20.  
A major contribution is Colipa´s €25 million funding commitment in the context of the call 
for proposals in relation to repeated dose systemic toxicity testing (see 3.2.3.) 
3.2.5. Others 
The ongoing activities mentioned in the 2007 report, such as the European Partnership for 
Alternative Approaches to Animal Testing (EPAA)21 the Community Action Plan on the 
Protection and Welfare of Animals22 and the revision of Directive 86/609/EEC on the 
protection of animals used in experiments23, were continued. 
                                                 
17 EUR 23886 – Alternative Testing Strategies – Progress Report 2009, Replacing, Reducing and refining 
use of animals in research, Genomics & Biotechnology for Health  
18 FP7-Health-2010-Alternative Testing 
19 SkinEthic Human Corneal Epithelium (HCE) model and the MatTek Epiocular model 
20 Human Cell Line Activation Test (h-CLAT), Myeloid U937 Skin Sensitisation Test (MUSST) and 
direct peptide reactivity assay (DPRA). 
21 For further information see http://www.ec.europa.eu/enterprise/epaa/index_en.htm 
22 COM (2006) 13 final, 23.1.2006 
23 For further information see http://ec.europa.eu/environment/chemicals/lab_animals/revision_en.htm 
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4. ACCEPTANCE AND RECOGNITION OF ALTERNATIVE METHODS AT INTERNATIONAL 
LEVEL 
The Commission has put the issues of validation and regulatory acceptance of alternative 
methods at the top of its agenda of sectoral regulatory dialogues at both multilateral and 
bilateral level. 
4.1. Multilateral level 
The Commission continues to actively work with its counterparts from the United States, 
Japan and Canada in the framework of the "International Cooperation on Cosmetic 
Regulation" (“ICCR”). One focal point of ICCR is exploring hurdles in the international 
regulatory acceptance of alternative testing methods.  
Important progress has been made in the international cooperation on alternative test methods 
with the agreement on a Framework for International Cooperation on Alternative Test 
Methods (ICATM) in September 2008. In April 2009 representatives from the validation 
bodies signed a Memorandum of Cooperation promoting enhanced international cooperation 
and coordination on the scientific validation of non- and reduced-animal toxicity testing 
methods. 
 
In addition to these efforts, the Commission is cooperating with the OECD by regularly taking 
part in meetings and working groups, such as the OECD Working Group of the National 
Coordinators of the Test Guidelines Programme, the Endocrine Disrupters Testing and 
Assessment Task force and its subgroups, that deal with non-animal tests (e.g. Validation 
Management Group - Non-Animal), and other ad-hoc expert groups dealing with various 
alternative methods. 
4.2. Bilateral level 
Questions of validation and regulatory acceptance of alternative methods are also at the core 
of the various bilateral regulatory dialogues with the main trading partners. In particular: 
4.2.1. U.S. 
Making progress on issues of validation and regulatory acceptance of alternative methods is 
one of the key deliverables agreed under the Transatlantic Economic Framework, and this 
work is closely monitored by the Transatlantic Economic Council (TEC). Alternative 
Methods to Animal Testing are included in the TEC work programme 2009 until 2010 and the 
implementation of the ICATM and continuous dialogue in view of alternative methods 
(possible priorities) will remain high on the agenda. 
4.2.2. Japan 
Alternatives to animal testing have been repeatedly raised, particularly in the framework of 
the regulatory reform dialogues in 2006, 2007 and 2008 and Japan stressed its support of the 
activities of the Japanese Center for the Validation of Alternative Methods (JACVAM).  
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4.2.3. China 
Replacing animal testing for cosmetics continues to be discussed in numerous fora, and in 
particular at an AQSIQ24-DG ENTR Working Group meeting on Cosmetics on 17 November 
2008 and in meetings with the SFDA25 and AQSIQ in January 2009. There is basic agreement 
that China must be more involved in the development of alternative methods. 
5. CONCLUSION 
Member States have improved their internal structure in order to provide for accurate animal 
testing data and effective monitoring of the application of the testing and marketing bans, as 
was encouraged in the guidelines annexed to the request to Member States for accurate data26. 
Nevertheless enforcement of the testing and marketing ban continues to pose challenges in 
relation to multiple use substances.  
Regarding the 2009 deadline, of the seven end points relevant for cosmetic products safety, 
replacement alternative methods are currently available for five. For the two remaining end 
points, “eye irritation” and “acute toxicity”, progress is being made but the deadlines for full 
replacement could not be met. Progress has been good and the Commission expects that the 
last two human health effects might be covered in the course of 2010. In the interim, industry 
can rely on data of tests performed before the March 2009 deadline. 
Regarding the 2013 deadline, the situation is much more critical. The replacement of animal 
test methods by alternative methods in relation to complex toxicological endpoints remains 
scientifically difficult, despite the significant additional efforts that have been launched at 
various levels. The situation will be thoroughly analysed during the preparation of the study 
required under the Cosmetics Directive for 2011.  
 
                                                 
24 General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of 
China 
25 State Food and Drug Administration China 
26 See paragraph 2.3. 
